Clinical Trials Browser

Interventional × Brentuximab Vedotin × Genitourinary × Clear all

NCT04254107 2025-02-10

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Triple Negative Breast Neoplasms

NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Phase 2 Terminated

18 enrolled 13 charts

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT01851200 2018-02-07

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Phase 2 Completed

Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal